NCT06363734 2024-04-16
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting